Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03995030
Other study ID # NYMC 181
Secondary ID
Status Completed
Phase
First received
Last updated
Start date September 15, 2016
Est. completion date December 31, 2021

Study information

Verified date October 2022
Source New York Medical College
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Patients who are post hematopoietic stem cell transplantation who require a bronchoalveolar lavage (BAL) for standard clinical car will have extra fluid collected and sent for massively parallel sequencing to see if it is as sensitive for detecting a microbial pulmonary infection compared to standard cultures.


Description:

5.1 Subjects will undergo bronchoscopy and BAL based on clinical indications. Techniques and equipment will be per current clinical practice at Westchester Medical Center (WMC). The bronchoscope is usually introduced either via an artificial airway (endotracheal tube or laryngeal mask airway). The lavage is performed with sterile normal saline. The site of performing the lavage is selected based on radiologic or clinical data and on the appearance of the airways during the bronchoscopy. The typical volume of the lavage is 3 aliquots of 1 ml/kg each, with a max of 20 ml per aliquot. 5.2 When 10 ml or more of BAL fluid is received by the WMC laboratory, the BAL fluid will be divided by the WMC laboratory for all physician ordered clinical laboratory tests and for massively parallel sequencing research tests. This will ensure that sufficient BAL material is available for all clinical tests. 5.3 The BAL fluid for research will be held by the WMC laboratory and picked up by research personnel for processing at New York Medical College Genomics Core Facility. 5.4 The research portion will be further divided for isolation of viral, bacterial, and fungal nucleic acid isolation. A control sample of fluid used for the BAL will be prepared in parallel. Bacterial/fungal DNA and viral DNA and RNA will be isolated. Whole genome sequencing libraries will be generated and sequenced in batches on the Illumina MiSeq. FASTQ files will be demultiplexed and then aligned to microbial genomes using Phylosift.11 DNA sequences present in both the patient and control samples will be discarded as contaminant. The preponderant organism(s) identified will be matched to the results of the culture based techniques used to verify the culture independent results.


Recruitment information / eligibility

Status Completed
Enrollment 10
Est. completion date December 31, 2021
Est. primary completion date January 31, 2019
Accepts healthy volunteers No
Gender All
Age group 0 Years to 29 Years
Eligibility Inclusion criteria - Patient age < 30 years - Recipient of an autologous or allogeneic stem cell transplant in the previous 365 days - Requires a bronchoalveolar lavage for clinical indications - Signed consent Exclusion criteria - Lack of signed informed consent

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
massively paralleled sequencing
Whole genome sequencing libraries will be generated and sequenced in batches on the Illumina MiSeq. FASTQ files will be demultiplexed and then aligned to microbial genomes using Phylosift.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
New York Medical College

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage concordance between massively paralleled sequencing (MPS) and standard microbiological technique results. Children, adolescents and young adult (CAYA) hematopoietic stem cell transplantation (HSCT) subjects with clinical symptoms/indications will undergo bronchoalveolar lavage (BAL), with samples from those with sufficient BAL fluid yield (>10ml) undergoing both massively paralleled sequencing and standard microbiological technique comparison. 10 days
See also
  Status Clinical Trial Phase
Recruiting NCT03687177 - Visual Cue as Prevention of Pulmonary Infection Under Mechanical Ventilation N/A
Recruiting NCT05552872 - Study on Diagnosis Value of mNGS Technology Among Diabetic Patients With Pulmonary Infections
Not yet recruiting NCT04583046 - Effects of Iloprost on Pulmonary Oxygenation in Obese Patients During One-lung Ventilation N/A
Recruiting NCT04624490 - Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease Phase 1
Recruiting NCT05505487 - Construction and Effect Evaluation of Integrated Care Model for Pulmonary Infection in Stroke Patients With Tracheotomy N/A
Terminated NCT04348513 - Triiodothyronine for the Treatment of Critically Ill Patients With COVID-19 Infection Phase 2
Completed NCT03438383 - Bi-PAP vs Sham Bi-PAP on Pulmonary Function in Morbidly Obese Patients After Bariatric Surgery N/A
Completed NCT03933878 - Rapid Detection of Airway Pathogens for Lung Transplantation
Completed NCT05844215 - MMP-9, TIMP-9 in Lung Imaging and Functional of COVID-19
Completed NCT02779595 - Change of Regional Ventilation During Spontaneous Breathing After Lung Surgery N/A
Recruiting NCT06368388 - Bacteriophage Therapy for Difficult-to-treat Infections: the Implementation of a Multidisciplinary Phage Task Force
Recruiting NCT04457609 - Administration of Allogenic UC-MSCs as Adjuvant Therapy for Critically-Ill COVID-19 Patients Phase 1
Completed NCT01525121 - Expiratory Rib Cage Compression in Mechanically Ventilated Patients N/A
Active, not recruiting NCT03617393 - Study on Appropriate Technology of Standardized Diagnosis and Treatment for Diabetic Patients With Pulmonary Infections
Completed NCT05226403 - COVID-19 : Pulmonary Ultrasound in Primary Care
Terminated NCT04422691 - Ultrasonography in Norwegian Emergency Department Patients With Suspected Covid-19 Infection
Completed NCT04553315 - the Effect of Chest Expansion Exercises on Pleural Effusion N/A
Recruiting NCT06282835 - Eravacycline Combination Therapy for MRAB
Completed NCT02419196 - Perioperative Change of Regional Ventilation During Spontaneous Breathing N/A
Completed NCT01058356 - Effect of Probiotic Lactobacilli (Lacidofil Cap®) for the Prevention of Antibiotic-Associated Diarrhea N/A